9cdb8246-eedc-40e2-b340-52db1edd0838
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.460
- OXIDATIVE_PHOSPHORYLATION+0.460
- PROTEIN_SECRETION+0.400
- ANDROGEN_RESPONSE+0.330
- MTORC1_SIGNALING+0.330
- FATTY_ACID_METABOLISM+0.320
- SPERMATOGENESIS+0.290
- E2F_TARGETS+0.240
- PEROXISOME+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.210
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- NOTCH_SIGNALING-0.370
- WNT_BETA_CATENIN_SIGNALING-0.340
- MYOGENESIS-0.320
- APICAL_JUNCTION-0.310
- APICAL_SURFACE-0.280
- ANGIOGENESIS-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- HEDGEHOG_SIGNALING-0.200
- UV_RESPONSE_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TXZ7KHTQ | high-grade glioma | — | 0.851 |
| 2 | R135 | — | — | 0.841 |
| 3 | 4f77bbd8-bf22-4cf9-8a16-5057e30ed148 | — | — | 0.833 |
| 4 | SRR1797282 | — | cohortSC | 0.809 |
| 5 | SRR26320065 | — | — | 0.808 |
| 6 | SJEPD030930_D1.RNA-Seq | EPN | EPN Tumor | 0.807 |
| 7 | TCGA-BH-A1F8-01A-11R-A13Q-07 | — | B | 0.804 |
| 8 | SRR17866853 | — | — | 0.796 |
| 9 | SRR1797281 | — | cohortSC | 0.795 |
| 10 | 518420d3-dfdf-4163-99a4-2b8d7a04056c | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |